Sycamore Labs | $65,000,000 | (Mar 31, 2026)
Deccan AI | $25,000,000 | (Mar 31, 2026)
Stedi | $50,000,000 | (Mar 31, 2026)
A-Alpha Bio
United States
- Seattle, Washington
- 26/07/2023
- Series A
- $22,400,000
At A-Alpha Bio, we aim to accelerate target discovery, library screening, and preclinical drug characterization by providing cell-based tools for quantitative and high-throughput measurements of protein interactions.
Current approaches for measuring protein interactions are insufficient for many drug development applications due to low accuracy or throughput. We are a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck. AlphaSeq is a revolutionary cell-based platform technology that will fundamentally change the way that protein interactions are measured. We are seeking industry partnerships to evaluate the use of AlphaSeq for a variety of drug development applications.
A-Alpha Bio, Inc. was founded in 2017 as a spinout from the University of Washington's Institute for Protein Design and Center for Synthetic Biology.
- Industry Biotechnology Research
- Website https://www.aalphabio.com/
- LinkedIn https://www.linkedin.com/company/aalphabio/
Related People
David YoungerCo Founder
United States -
Seattle, Washington
A-Alpha Bio partners with pharmaceutical companies to discover and optimize high-impact therapeutics.
OpenBox AI | $5,000,000 | (Mar 31, 2026)
Qodo | $70,000,000 | (Mar 31, 2026)
Starcloud | $170,000,000 | (Mar 31, 2026)
Valinor(1) | $25,000,000 | (Mar 31, 2026)
Mars Men | $27,500,000 | (Mar 31, 2026)
Scalvy | $13,900,000 | (Mar 27, 2026)
SIGMAS | $1,000,000 | (Mar 27, 2026)
CurrentClient | $1,250,000 | (Mar 27, 2026)
VITL | $7,500,000 | (Mar 27, 2026)